Yet the opportunity remains significant. With a growing pipeline of clinical programs, an expanding portfolio of approved therapies and increasing commercial revenues, the sector is demonstrating its potential. The question now is how the industry can translate that momentum into sustainable growth, overcome barriers to patient access and deliver advanced therapies at scale.
The scale of activity across the sector demonstrates just how far the field has progressed. More than 2,000 CGT clinical trials are currently underway globally, while 122 CGTs had been approved as of April 2026, comprising 46 gene therapies, including genetically modified cell therapies, and 76 non-genetically modified cell therapies. Four CGTs are now generating more than $1 billion in annual revenue, underlining the sector's growing commercial maturity.
$146 billion
Projected global CGT market value by 2032
10–20
New CGT approvals expected annually through 2030
Together, these figures point to an industry moving beyond proof of scientific concept and toward a more demanding challenge: developing, manufacturing and delivering therapies at the scale needed to make a meaningful impact.
From the investment environment and manufacturing readiness to emerging delivery technologies, regional growth and patient access, understanding the forces shaping the CGT landscape has never been more important.
Explore the Full CGT Landscape
Discover the five themes shaping the next phase of cell and gene therapy, with insights into investment, manufacturing, delivery innovation, regional growth and patient access.
)